GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » Net Income (Discontinued Operations)

D&D Pharmatech (XKRX:347850) Net Income (Discontinued Operations) : ₩0 Mil (TTM As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is D&D Pharmatech Net Income (Discontinued Operations)?

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods. D&D Pharmatech's Net Income (Discontinued Operations) for the three months ended in Mar. 2025 was ₩0 Mil. Its Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Mar. 2025 was ₩0 Mil.

D&D Pharmatech Net Income (Discontinued Operations) Historical Data

The historical data trend for D&D Pharmatech's Net Income (Discontinued Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

D&D Pharmatech Net Income (Discontinued Operations) Chart

D&D Pharmatech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income (Discontinued Operations)
Get a 7-Day Free Trial - - - - -

D&D Pharmatech Quarterly Data
Dec18 Dec19 Dec20 Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income (Discontinued Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

D&D Pharmatech Net Income (Discontinued Operations) Calculation

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods.

Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

D&D Pharmatech Net Income (Discontinued Operations) Related Terms

Thank you for viewing the detailed overview of D&D Pharmatech's Net Income (Discontinued Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

D&D Pharmatech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » Net Income (Discontinued Operations)
Comparable Companies
XKRX:358570 XKRX:226950 XKRX:086900 XKRX:950210 XKRX:005690 XKRX:085660 XKRX:005250 XKRX:115450 XKRX:053030 XKRX:048410 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
4th floor, 24, Pangyo-ro 255beon-gil, Bundang-gu, Gyeonggi-do, Sampyeong-dong, I&C Building, Seongnam-si, KOR
Website
http://www.ddpharmatech.com
D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.

D&D Pharmatech Headlines

No Headlines